Quick Takes Aug. 17: InnoCare gains China rights to Incyte’s Monjuvi
Plus: Neuroblastoma approval for BeiGene, priority review for Agios’ mitapivat, Arctic Vision, Vectura, AnaptysBio and more
InnoCare Pharma Ltd. (HKEX:9969) added to its large-molecule pipeline by obtaining local rights to Monjuvi tafasitamab-cxix from Incyte Corp. (NASDAQ:INCY), setting up the Beijing-based company to study the Fc-optimized, CD19-targeting mAb in combination with its Btk inhibitor orelabrutinib. InnoCare is paying $35 million up front for Monjuvi’s rights in mainland China, Hong Kong, Macau and Taiwan; Incyte is eligible for $82.5 million in milestones, plus royalties. FDA has approved Monjuvi to treat diffuse large B-cell lymphoma (DLBCL).
NMPA granted conditional approval to Qarziba dinutuximab beta from BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) for high-risk neuroblastoma in patients 12 months and older. The approval was supported by results from trials conducted by SIOPEN with the support of Aperion Biologics Inc. and EUSA Pharma Ltd. EMA has approved the mAb directed against carbohydrate moiety of GD2 for the indication...